Revised forecast
Fiscal year ending September 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Operating profit and ordinary profit are expected to increase through the concentration of management resources on highly profitable businesses and the further creation of business synergies with SBC Medical Group. In the fiscal year ended September 2026, the tax burden was temporarily low due to the utilization of tax loss carryforwards and a reassessment of the recoverability of deferred tax assets. Accordingly, the company expects the tax burden for the fiscal year ending September 2027 to be based on normal levels, resulting in a decline in net income.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥4,151 million（38.8% (year on year)） |
| Operating profit | Not disclosed → ¥880 million（27.2% (year on year)） |
| Ordinary income | Not disclosed → ¥870 million（27.1% (year on year)） |
| Profit attributable to owners of the parent | Not disclosed → ¥521 million（-30.8% (year on year)） |
| Net income per share | Not disclosed → ¥146.85 / sen |
| Fiscal Period Covered | Fiscal year ending September 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended September 2026: net sales ¥2,990 million, operating profit ¥691 million, ordinary profit ¥684 million, net income attributable to owners of the parent ¥752 million, basic earnings per share ¥212.07 |
| Reason for the revision | Operating profit and ordinary profit are expected to increase through the concentration of management resources on highly profitable businesses and the further creation of business synergies with SBC Medical Group. In the fiscal year ended September 2026, the tax burden was temporarily low due to the utilization of tax loss carryforwards and a reassessment of the recoverability of deferred tax assets. Accordingly, the company expects the tax burden for the fiscal year ending September 2027 to be based on normal levels, resulting in a decline in net income. |
| Dividend forecast revision | The annual dividend forecast for the fiscal year ending September 2027 is ¥0.00 (interim ¥0.00, year-end ¥0.00). No statement indicates that this is a revision to the dividend forecast. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company expects operating profit and ordinary profit to increase through a structural shift in its business portfolio centered on the Medical Support business, the concentration of management resources on highly profitable businesses, and the creation of synergies with SBC Medical Group. In the fiscal year ended September 2026, the tax burden was temporarily low due to the utilization of tax loss carryforwards and a reassessment of the recoverability of deferred tax assets. Accordingly, the company expects the tax burden for the fiscal year ending September 2027 to be based on normal levels, resulting in a decline in net income.